Fabregat-Franco, C. http://orcid.org/0000-0003-2292-2690
Stradella, A.
Navarro, V.
Linares, J.
Galdeano, M.
Recalde, S.
Velasco, R.
Simo, M.
Fernadez, A.
Venthecourt, A. C.
Falo, C.
Vazquez, S.
Bergamino, M.
Villanueva, R.
Pernas, S.
Gil-Gil, M. J.
Article History
Received: 20 January 2021
Accepted: 19 February 2021
First Online: 11 March 2021
Declarations
:
: MG declares consulting/advisory fees from Pfizer, Eisai, Genomic-Health, Agendia, Daiichi-Sankyo, Novartis, Roche Pharma and Kern and travel/accommodation grants from Daiichi-Sankyo, Kern, Novartis and Pfizer. SP declares consulting/advisory fees from Astra-Zeneca, Daiichi-Sankyo, Novartis, Polyphor and Roche and travel/accommodation grants from Novartis. CFZ declares facilities to congress attendance from Pfizer. RVV declares professional fees from Novartis, Pfizer and Roche. RVF declares professional fees from Novartis, Gilead, Eisai, Esteve and Takeda. The rest of the authors have no conflicts of interest to declare.
: The protocol and the informed consent were approved by the Ethics Committee of University Hospital of Bellvitge (PR189/20). (Appendix 1in ESM).
: Patients included prospectively signed the informed consent approved by ethics committee (Appendix 2in ESM).